Abstract
3562 Background: TRIBE, a phase III randomized trial comparing FOLFIRI + BEV (Arm A) vs FOLFOXIRI + BEV (Arm B) as first-line treatment for mCRC, were recently published in the NEJM. No known predi...
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
